Review



automated patch clamp method qpatch htx  (WuXi AppTec)


Bioz Verified Symbol WuXi AppTec is a verified supplier
Bioz Manufacturer Symbol WuXi AppTec manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    WuXi AppTec automated patch clamp method qpatch htx
    Automated Patch Clamp Method Qpatch Htx, supplied by WuXi AppTec, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/automated+patch-clamp+platform+qpatch/manual+patch+clamp+technique/pmc04432195-38-7-13
    Average 90 stars, based on 1 article reviews
    automated patch clamp method qpatch htx - by Bioz Stars, 2026-11
    90/100 stars

    Images

    Related Articles

    Inhibition:

    Article Title: Enantiomers of Nifurtimox Do Not Exhibit Stereoselective Anti- Trypanosoma cruzi Activity, Toxicity, or Pharmacokinetic Properties
    Article Snippet: .. For the hERG inhibition assay, an automated patch clamp method (QPatch HTX ; WuXi AppTec Co., Ltd., Shanghai, China) was used and indicated that neither of the enantiomers exhibited detectable inhibition of the channel (50% inhibitory concentration [IC 50 ] > 30 μM). .. A mini-Ames assay (WuXi AppTec Ltd., Suzhou, China) using Salmonella enterica serovar Typhimurium strains TA98 and TA100 in the presence or absence of exogenous metabolic activation (Aroclor 1254-induced rat liver S9 mix) turned out positive for each enantiomer (>2-fold increase in the mean number of revertant colonies); a similar increase in the number of revertants per plate (reverse mutations at the selected loci of the two tester strains) in the absence or presence of S9 activation was exhibited by each enantiomer.

    Article Title: Synthesis and characterization of chiral 6-azaspiro[2.5]octanes as potent and selective antagonists of the M 4 muscarinic acetylcholine receptor.
    Article Snippet: In this manuscript, we report a series of chiral 6-azaspiro[2.5]octanes and related spirocycles as highly potent and selective antagonists of the muscarinic acetylcholine receptor subtype 4 (mAChR4).. Chiral separation and subsequent X-ray crystallographic analysis of early generation analogs revealed the R enantiomer to possess excellent human and rat M4 potency, and further structure–activity relationship (SAR) studies on this chiral scaffold led to the discovery of VU6015241 (compound 19).. Compound 19 is characterized by high M4 potency and selectivity across multiple species, excellent aqueous solubility, and moderate brain exposure in rodents after intraperitoneal administration.

    Patch Clamp:

    Article Title: Enantiomers of Nifurtimox Do Not Exhibit Stereoselective Anti- Trypanosoma cruzi Activity, Toxicity, or Pharmacokinetic Properties
    Article Snippet: .. For the hERG inhibition assay, an automated patch clamp method (QPatch HTX ; WuXi AppTec Co., Ltd., Shanghai, China) was used and indicated that neither of the enantiomers exhibited detectable inhibition of the channel (50% inhibitory concentration [IC 50 ] > 30 μM). .. A mini-Ames assay (WuXi AppTec Ltd., Suzhou, China) using Salmonella enterica serovar Typhimurium strains TA98 and TA100 in the presence or absence of exogenous metabolic activation (Aroclor 1254-induced rat liver S9 mix) turned out positive for each enantiomer (>2-fold increase in the mean number of revertant colonies); a similar increase in the number of revertants per plate (reverse mutations at the selected loci of the two tester strains) in the absence or presence of S9 activation was exhibited by each enantiomer.

    Article Title: Synthesis and characterization of chiral 6-azaspiro[2.5]octanes as potent and selective antagonists of the M 4 muscarinic acetylcholine receptor.
    Article Snippet: In this manuscript, we report a series of chiral 6-azaspiro[2.5]octanes and related spirocycles as highly potent and selective antagonists of the muscarinic acetylcholine receptor subtype 4 (mAChR4).. Chiral separation and subsequent X-ray crystallographic analysis of early generation analogs revealed the R enantiomer to possess excellent human and rat M4 potency, and further structure–activity relationship (SAR) studies on this chiral scaffold led to the discovery of VU6015241 (compound 19).. Compound 19 is characterized by high M4 potency and selectivity across multiple species, excellent aqueous solubility, and moderate brain exposure in rodents after intraperitoneal administration.

    Concentration Assay:

    Article Title: Enantiomers of Nifurtimox Do Not Exhibit Stereoselective Anti- Trypanosoma cruzi Activity, Toxicity, or Pharmacokinetic Properties
    Article Snippet: .. For the hERG inhibition assay, an automated patch clamp method (QPatch HTX ; WuXi AppTec Co., Ltd., Shanghai, China) was used and indicated that neither of the enantiomers exhibited detectable inhibition of the channel (50% inhibitory concentration [IC 50 ] > 30 μM). .. A mini-Ames assay (WuXi AppTec Ltd., Suzhou, China) using Salmonella enterica serovar Typhimurium strains TA98 and TA100 in the presence or absence of exogenous metabolic activation (Aroclor 1254-induced rat liver S9 mix) turned out positive for each enantiomer (>2-fold increase in the mean number of revertant colonies); a similar increase in the number of revertants per plate (reverse mutations at the selected loci of the two tester strains) in the absence or presence of S9 activation was exhibited by each enantiomer.

    Article Title: Synthesis and characterization of chiral 6-azaspiro[2.5]octanes as potent and selective antagonists of the M 4 muscarinic acetylcholine receptor.
    Article Snippet: In this manuscript, we report a series of chiral 6-azaspiro[2.5]octanes and related spirocycles as highly potent and selective antagonists of the muscarinic acetylcholine receptor subtype 4 (mAChR4).. Chiral separation and subsequent X-ray crystallographic analysis of early generation analogs revealed the R enantiomer to possess excellent human and rat M4 potency, and further structure–activity relationship (SAR) studies on this chiral scaffold led to the discovery of VU6015241 (compound 19).. Compound 19 is characterized by high M4 potency and selectivity across multiple species, excellent aqueous solubility, and moderate brain exposure in rodents after intraperitoneal administration.

    other:

    Article Title: Optimizing Pyrazolopyrimidine Inhibitors of Calcium Dependent Protein Kinase 1 for Treatment of Acute and Chronic Toxoplasmosis
    Article Snippet: Compounds were tested by WuXi AppTec for inhibition of hERG (human ether-à-go-go-related gene) potassium channels stably expressed in a CHO cell line using manual patch-clamp technique.

    Article Title: A Novel, Selective c-Abl Inhibitor, Compound 5, Prevents Neurodegeneration in Parkinson's Disease.
    Article Snippet: Parkinson’s disease (PD) is a progressive neurodegenerative disorder that affects movement.. The nonreceptor tyrosine kinase c-Abl has shown a potential role in the progression of PD.. As such, c-Abl inhibition is a promising candidate for neuroprotection in PD and α-synucleinopathies.

    Article Title: Discovery of a Novel Bifunctional Steroid Analog, YXG-158, as an Androgen Receptor Degrader and CYP17A1 Inhibitor for the Treatment of Enzalutamide-Resistant Prostate Cancer.
    Article Snippet: The androgen/androgen receptor (AR) signaling pathway plays an important role in castration-resistant prostate cancer (CRPC).. Bifunctional agents that simultaneously degrade AR and inhibit androgen synthesis are expected to block the androgen/AR signaling pathway more thoroughly, demonstrating the promising therapeutic potential for CRPC, even enzalutamideresistant CRPC.. Herein, a series of steroid analogs were designed, synthesized, and identified as selective AR degraders, among which YXG-158 (23-h) was the most potent antitumor compound with dual functions of AR degradation and CYP17A1 inhibition.

    Article Title: Optimizing Pyrazolopyrimidine Inhibitors of Calcium Dependent Protein Kinase 1 for Treatment of Acute and Chronic Toxoplasmosis.
    Article Snippet: Compounds were tested by WuXi AppTec for inhibition of hERG (human ether-a-̀go-go-related gene) potassium channels stably expressed in a CHO cell line using manual patch-clamp technique.

    Article Title: 7-Substituted 2-Nitro-5,6-dihydroimidazo[2,1-b][1,3]oxazines: Novel Antitubercular Agents Lead to a New Preclinical Candidate for Visceral Leishmaniasis
    Article Snippet: The effects of compounds 44 and 79 on cloned hERG potassium channels expressed in Chinese hamster ovary cells were assessed by WuXi AppTec (Shanghai) Co., Ltd., using the automated patch clamp method.

    Article Title: DNDI-6148: A Novel Benzoxaborole Preclinical Candidate for the Treatment of Visceral Leishmaniasis
    Article Snippet: An automated patch-clamp method (QPatch HTX) was used by WuXi AppTec, China.

    Clinical Proteomics:

    Article Title: Synthesis and characterization of chiral 6-azaspiro[2.5]octanes as potent and selective antagonists of the M 4 muscarinic acetylcholine receptor.
    Article Snippet: In this manuscript, we report a series of chiral 6-azaspiro[2.5]octanes and related spirocycles as highly potent and selective antagonists of the muscarinic acetylcholine receptor subtype 4 (mAChR4).. Chiral separation and subsequent X-ray crystallographic analysis of early generation analogs revealed the R enantiomer to possess excellent human and rat M4 potency, and further structure–activity relationship (SAR) studies on this chiral scaffold led to the discovery of VU6015241 (compound 19).. Compound 19 is characterized by high M4 potency and selectivity across multiple species, excellent aqueous solubility, and moderate brain exposure in rodents after intraperitoneal administration.

    In Vitro:

    Article Title: Synthesis and characterization of chiral 6-azaspiro[2.5]octanes as potent and selective antagonists of the M 4 muscarinic acetylcholine receptor.
    Article Snippet: In this manuscript, we report a series of chiral 6-azaspiro[2.5]octanes and related spirocycles as highly potent and selective antagonists of the muscarinic acetylcholine receptor subtype 4 (mAChR4).. Chiral separation and subsequent X-ray crystallographic analysis of early generation analogs revealed the R enantiomer to possess excellent human and rat M4 potency, and further structure–activity relationship (SAR) studies on this chiral scaffold led to the discovery of VU6015241 (compound 19).. Compound 19 is characterized by high M4 potency and selectivity across multiple species, excellent aqueous solubility, and moderate brain exposure in rodents after intraperitoneal administration.



    Similar Products

    90
    Sophion Bioscience qpatch automated patch-clamp platform
    Na v channel compound profile assessed on the Qube or <t>Qpatch*.</t> Ten-point titrations in the Qube automated patch-clamp assay determined MSD199 to be a potent and selective compound (IC 50 = 4.7 ± 0.8 nM, mean ± SD). MSD199 potency was too weak to calculate for all other Na v isoforms except Na v 1.4, which was 1781-fold shifted to 8370 nM mean IC 50 ± 1429.
    Qpatch Automated Patch Clamp Platform, supplied by Sophion Bioscience, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/automated+patch-clamp+platform+qpatch/qpatch+16+automated+electrophysiology+platform/pmc11808707-32-55-59
    Average 90 stars, based on 1 article reviews
    qpatch automated patch-clamp platform - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    Sophion Bioscience automated patch clamp platform qpatch
    Na v channel compound profile assessed on the Qube or <t>Qpatch*.</t> Ten-point titrations in the Qube automated patch-clamp assay determined MSD199 to be a potent and selective compound (IC 50 = 4.7 ± 0.8 nM, mean ± SD). MSD199 potency was too weak to calculate for all other Na v isoforms except Na v 1.4, which was 1781-fold shifted to 8370 nM mean IC 50 ± 1429.
    Automated Patch Clamp Platform Qpatch, supplied by Sophion Bioscience, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/automated+patch-clamp+platform+qpatch/qpatch+16+automated+electrophysiology+platform/us11944623-637-7-11
    Average 90 stars, based on 1 article reviews
    automated patch clamp platform qpatch - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    Sophion Bioscience qpatch-16 automated patch-clamp electrophysiology platform
    Na v channel compound profile assessed on the Qube or <t>Qpatch*.</t> Ten-point titrations in the Qube automated patch-clamp assay determined MSD199 to be a potent and selective compound (IC 50 = 4.7 ± 0.8 nM, mean ± SD). MSD199 potency was too weak to calculate for all other Na v isoforms except Na v 1.4, which was 1781-fold shifted to 8370 nM mean IC 50 ± 1429.
    Qpatch 16 Automated Patch Clamp Electrophysiology Platform, supplied by Sophion Bioscience, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/automated+patch-clamp+platform+qpatch/qpatch+16+automated+electrophysiology+platform/pm37262436-184-6-11
    Average 90 stars, based on 1 article reviews
    qpatch-16 automated patch-clamp electrophysiology platform - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    Sophion Bioscience automated patch-clamp platform qpatch
    Na v channel compound profile assessed on the Qube or <t>Qpatch*.</t> Ten-point titrations in the Qube automated patch-clamp assay determined MSD199 to be a potent and selective compound (IC 50 = 4.7 ± 0.8 nM, mean ± SD). MSD199 potency was too weak to calculate for all other Na v isoforms except Na v 1.4, which was 1781-fold shifted to 8370 nM mean IC 50 ± 1429.
    Automated Patch Clamp Platform Qpatch, supplied by Sophion Bioscience, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/automated+patch-clamp+platform+qpatch/qpatch+16+automated+electrophysiology+platform/pm34971874-431-7-10
    Average 90 stars, based on 1 article reviews
    automated patch-clamp platform qpatch - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    Sophion Bioscience qpatch automated patch clamp platform
    Na v channel compound profile assessed on the Qube or <t>Qpatch*.</t> Ten-point titrations in the Qube automated patch-clamp assay determined MSD199 to be a potent and selective compound (IC 50 = 4.7 ± 0.8 nM, mean ± SD). MSD199 potency was too weak to calculate for all other Na v isoforms except Na v 1.4, which was 1781-fold shifted to 8370 nM mean IC 50 ± 1429.
    Qpatch Automated Patch Clamp Platform, supplied by Sophion Bioscience, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/automated+patch-clamp+platform+qpatch/qpatch+16+automated+electrophysiology+platform/pm30999054-54-8-13
    Average 90 stars, based on 1 article reviews
    qpatch automated patch clamp platform - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    Sophion Bioscience automated patch-clamp platform qpatch 16
    Na v channel compound profile assessed on the Qube or <t>Qpatch*.</t> Ten-point titrations in the Qube automated patch-clamp assay determined MSD199 to be a potent and selective compound (IC 50 = 4.7 ± 0.8 nM, mean ± SD). MSD199 potency was too weak to calculate for all other Na v isoforms except Na v 1.4, which was 1781-fold shifted to 8370 nM mean IC 50 ± 1429.
    Automated Patch Clamp Platform Qpatch 16, supplied by Sophion Bioscience, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/automated+patch-clamp+platform+qpatch/qpatch+16+automated+electrophysiology+platform/pm28322838-46-7-11
    Average 90 stars, based on 1 article reviews
    automated patch-clamp platform qpatch 16 - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    Image Search Results


    Na v channel compound profile assessed on the Qube or Qpatch*. Ten-point titrations in the Qube automated patch-clamp assay determined MSD199 to be a potent and selective compound (IC 50 = 4.7 ± 0.8 nM, mean ± SD). MSD199 potency was too weak to calculate for all other Na v isoforms except Na v 1.4, which was 1781-fold shifted to 8370 nM mean IC 50 ± 1429.

    Journal: Pain

    Article Title: Analgesia and peripheral c-fiber modulation by selective Na v 1.8 inhibition in rhesus

    doi: 10.1097/j.pain.0000000000003404

    Figure Lengend Snippet: Na v channel compound profile assessed on the Qube or Qpatch*. Ten-point titrations in the Qube automated patch-clamp assay determined MSD199 to be a potent and selective compound (IC 50 = 4.7 ± 0.8 nM, mean ± SD). MSD199 potency was too weak to calculate for all other Na v isoforms except Na v 1.4, which was 1781-fold shifted to 8370 nM mean IC 50 ± 1429.

    Article Snippet: Qube voltage-clamp experiments were performed using human embryonic kidney (HEK) 293 cell lines or Chinese Hamster Ovary cell lines stably expressing either human Na v 1.1, Na v 1.2, Na v 1.3, Na v 1.4, Na v 1.5, Na v 1.6, Na v 1.7, Na v 1.8, or Na v 1.9 on the Qube or Qpatch automated patch-clamp platforms (Sophion Bioscience A/S, Ballerup, Denmark).

    Techniques: Patch Clamp